Extended Data Table 4 Grade 3/4 adverse events of special interest
Patients, n (%) | Neoadjuvant phase | Overall | ||
|---|---|---|---|---|
Atezolizumab + CT (n = 164) | Placebo + CT (n = 167) | Atezolizumab + CT (n = 164) | Placebo + CT (n = 167) | |
Hepatitis (diagnosis and laboratory abnormalities) | 16 (10) | 13 (8) | 17 (10) | 13 (8) |
Hepatitis (diagnosis) | 1 (1) | 0 | 1 (1) | 0 |
Hepatitis (laboratory abnormalities) | 15 (9) | 13 (8) | 16 (10) | 13 (8) |
Rash | 6 (4) | 6 (4) | 6 (4) | 6 (4) |
Colitis | 1 (1) | 0 | 2 (1) | 0 |
Infusion-related reaction | 1 (1) | 1 (1) | 1 (1) | 1 (1) |
Pneumonitis | 1 (1) | 0 | 1 (1) | 1 (1) |
Meningoencephalitis | 1 (1) | 0 | 1 (1) | 0 |
Myositis | 1 (1) | 0 | 1 (1) | 0 |
Autoimmune hemolytic anemia | 1 (1) | 0 | 1 (1) | 0 |
Pancreatitis | 0 | 0 | 1 (1) | 0 |
Guillain–Barré syndrome | 0 | 1 (1) | 0 | 1 (1) |
Hypothyroidism | 0 | 0 | 0 | 0 |
Hyperthyroidism | 0 | 0 | 0 | 0 |
Adrenal insufficiency | 0 | 0 | 0 | 0 |
Diabetes | 0 | 0 | 0 | 0 |
Ocular inflammatory toxicity | 0 | 0 | 0 | 0 |
Severe cutaneous reactions | 0 | 0 | 0 | 0 |
